Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)

NCT01109888 | Withdrawn Phase 1 DMC

• 1 other identifier: 12101967
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Coasting is one of the means to reduce the risk of OHSS for patients at risk for severe OHSS. During coasting gonadotrophin administration is withheld until serum E2 levels drop to a range considered safe. Prolonged coasting reduces the chance for implantation and pregnancy. The aim of the study is to explore whether an increased dose of GnRH Antagonist will shorten the coasting period without an adverse effect on cycle outcome.

Conditions

Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)

Study Arms (1)

Cetrotide

ACTIVE COMPARATOR

Drug: Cetrotide

Interventions

Cetrotide DRUG

Cetrotide

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: female
• Age Groups: Adult (18-64)

You may qualify if:

• E2 higher than 3000 pg/ml. -

Sponsors & Collaborators

• Wolfson Medical Center: lead

MeSH Terms

Interventions

cetrorelix

Study Design

• Study Type: interventional
• Phase: phase 1
• Sponsor Type: OTHER GOV

Study Record Dates

• First Submitted: April 22, 2010
• First Posted: April 23, 2010
• Last Updated: March 30, 2016

Record last verified: 2010-04